Eitemau Tebyg: White Book - Celgene: An Abundance of Revlimid Opportunities in Myeloma, But Maintenance Is the Biggest Driver
- Black Book - Multiple Myeloma: Patients, Penetration Price & Duration Offer Upside for Celgene Through 2015
- White Book - European Food: Restructuring Is Not the Operating Panacea, But It Is an Investing Opportunity
- White Book - Multiple Myeloma: SCB Survey Highlights Growth Potential of New Agents
- Black Book - European Soft Drink Opportunity
- White Book - Commercial Aircraft: China - The Opportunity & the Threat
- Bernstein Black Book - U.S. Oil Services: Winds of Change - The Shifting Drivers of Service Intensity